secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-09-16T23:59:59+00:00
Accession:  0001213900-25-087925
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals receives FDA alignment on Phase 3 trial design for AD04 in alcohol use disorder
--------------------------------------------------------------------------------

- FDA End-of-Phase 2 meeting held July 29, 2025; final minutes received confirming alignment on adaptive Phase 3 design.
- FDA confirmed primary endpoint of zero heavy drinking days during months 5 and 6 of efficacy observation.
- FDA supported biomarker stratification (AG+ subgroup, ~14% of general population) and adaptive enrichment strategy.
- FDA advised pre-specifying key secondary endpoints in protocol for potential future product labeling.
- CEO highlights new patent filing that may extend AD04 market exclusivity to 2045.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025087925/0001213900-25-087925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025087925/ea0257511-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-087925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer